The incretin modulators - Incretin mimetics (GLP-1 Receptor Agonists) and incretin enhancers (DPP-4 Inhibitors)

Pharmacotherapy of Diabetes: New Developments: Improving Life and Prognosis for Diabetic Patients

Volumn , Issue , 2007, Pages 111-141

  Nauck, Michael A ^a   Schmidt, Wolfgang E ^a   Meier, Juris J ^a  

^a DIABETESZENTRUM BAD LAUTERBERG   (Germany)

Author keywords

DPP 4; entero insular axis; exenatide; gastric inhibitory polypeptide (GIP); glucagon like peptide 1 (GLP 1); Incretin; liraglutide; saxagliptin; sitagliptin; vildagliptin

Indexed keywords

EID: 78650717633     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-69737-6_12     Document Type: Chapter

References (250)

1. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.
2. Gromada J, Dissing S, Kofod H, Frokjaer-Jensen J. Effects of the hypoglycaemic drugs repaglinide and glibenclamide on ATP-sensitive potassium channels and cytosolic calcium levels in β?TC3 cells and rat pancreatic beta cells. Diabetologia 1995;38:1025-1032.
3. Creutzfeldt W. The incretin concept today. Diabetologia 1979;16:75-85.
4. Creutzfeldt W, Nauck M. Gut hormones and diabetes mellitus. Diabetes/Metab Rev 1992;8:149-177.
5. Brown JC, Pederson RA. GI hormones and insulin secretion. Endocrinology. Proceedings of the Vth International Congress Endocrinol 1976;2:568-570.
6. Brown JC, Dahl M, McIntosh CHS, Otte SC, Pedeson RA. Actions of GIP. Peptides 1981;2:241-245.
7. Brown JC. Gastric Inhibitory Polypeptide. Heidelberg: Springer-Verlag; 1982.
8. Pederson RA, Brown JC. The insulinotropic action of gastric inhibitory polypeptide in the perfused rat pancreas. Endocrinology 1976;99:780-785.
9. Dupré J, Ross SA, Watson D, Brown JC. Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocrinol Metab 1973;37:826-828.
10. Krarup T, Saurbrey N, Moody AJ, Kühl C, Madsbad S. Effect of porcine gastric inhibitory polypeptide on β-cell function in Type 1 and Type II diabetes mellitus. Metabolism 1988;36:677-682.
11. Nauck MA, Heimesaat MM, Ørskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993;91:301-307.
12. Meier JJ, Hücking K, Holst JJ, Deacon CF, Schmiegel WH, Nauck MA. Reduced insulinotropic effect of gastric inhibitory polypeptide in firstdegree relatives of patients with type 2 diabetes. Diabetes 2001;50:2497-2504.
13. Vilsbøll T, Krarup T, Madsbad S, Holst JJ. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia 2002;45:1111-1119.
14. Bell GI, Sanchez-Pescador R, Laybourn PJ, Najarian RC. Exon duplication and divergence in the human preproglucagon gene. Nature 1983;304:368-371.
15. Holst JJ, Oslash;rskov C, Vagn-Nielsen O, Schwartz TW. Truncated glucagon-like peptide 1, an insulinreleasing hormone from the distal gut. FEBS Letters 1987; 211: 169-174.
16. Mojsov S, Weir GC, Habener JF. Insulinotropin: glucagon-like peptide I (737) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest 1987;79:616-619.
17. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 [736]: a physiological incretin in man. Lancet 1987; 2: 1300-1304.
18. Nauck MA, Bartels E, Ørskov C, Ebert R, Creutzfeldt W. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(736) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 1993;76:912-917.
19. Nathan DM, Schreiber E, Fogel H, Mojsov S, Habener JF. Insulinotropic action of glucagon-like peptide 1 (737) in diabetic and nondiabetic subjects. Diabetes Care 1992;15:270-276.
20. Gutniak MK, Holst JJ, Ørskov C, Åhren B, Efendic S. Antidiabetogenic effect of glucagon-like peptide-1 (736) amide in normal subjects and patients with diabetes mellitus. N Engl J Med 1992;326:1316-1322.
21. Elrick H, Stimmler L, Hlad CJ, Arai Y. Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab 1964;24:1076-1082.
22. McIntyre N, Holdsworth CD, Turner DS. Intestinal factors in the control of insulin secretion. J Clin Endocrinol 1965;25:1317-1324.
23. Perley MJ, Kipnis DM. Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects. J Clin Invest 1967;46:1954-1962.
24. Brown JC, Dryburgh JR. A gastric inhibitory polypeptide II. The complete amino acid sequence. Can J Biochem 1971;49:867-872.
25. Pederson RA, Schubert HE, Brown JC. Gastric inhibitory polypeptide. Its physiologic release and insulinotropic action in the dog. Diabetes 1975;24:1050-1056.
26. Buchan AMJ, Polak JM, Capella C, Solcia E, Pearse AGE. Electron immunocytochemical evidence of the K cell localisation of gastric inhibitory polypeptide (GIP) in man. Histochemistry 1978;56:37-44.
27. Bell GI. The glucagon super family: Precursor structure and gene organization. Peptides 1986;7(Suppl. 1):27-36.
28. Eissele R, Göke R, Willemer S, Harthus HP, Vermeer H, Arnold R, et al. Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man. Eur J Clin Invest 1992;22:283-291.
29. Ørskov C, Knuhtsen S, Baldissera FG, Poulsen SS, Nielsen OV, Holst JJ. Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas. Endocrinology 1986;119:1467-1475.
30. Ørskov C, Holst JJ, Seier-Poulsen S, Kirkegaard P. Pancreatic and intestinal processing of proglucagon in man. Diabetologia 1987;30:874-881.
31. Blackmore PF, Mojsov S, Exton JH, Habener JF. Absence of insulinotropic glucagon-like peptide-I (737) receptors on isolated rat liver hepatocytes. FEBS Lett 1991;283:7-10.
32. Oslash;rskov C, Rabenhøj L, Wettergren A, Kofod H, Holst JJ. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide 1 in humans. Diabetes 1994;43:535-539.
33. Brubaker PL. Regulation of intestinal proglucagonderived peptide secretion by intestinal regulatory peptides. Endocrinol 1991;128:3175-3182.
34. Mortensen K, Petersen LL, Orskov C. Colocalization of GLP-1 and GIP in human and porcine intestine. Ann N Y Acad Sci 2000;921:469-472.
35. Nauck MA. Glucagon-like peptide 1 (GLP-1): a potent gut hormone with a possible therapeutic perspective. Acta Diabetol 1998;35:117-129.
36. Vilsbøll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001;50:609-613.
37. Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Host JJ. Both subcutaneously and intravenously administered glucagon-like peptide 1 are rapidly degraded from the NH2-terminus in type 2-diabetic patients and in healthy subjects. Diabetes 1995;44:1126-1131.
38. Mentlein R, Gallwitz B, Schmidt WE. Dipeptidylpeptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1 (736) amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 1993;214:829-835.
39. Mentlein R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept 1999;85:9-24.
40. Grandt D, Sieburg B, Sievert J, Schimiczek M, Becker U, Holtmann D. Is GLP-1 (936) amide an endogenous antagonist at GLP-1 receptors? (abstract). Digestion 1994;55:302.
41. Knudsen LB, Pridal L. Glucagon-like peptide-1-(936) amide is a major metabolite of glucagon-like peptide-1-(736) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. Eur J Pharmacol 1996;318:429-435.
42. Deacon CF, Plamboeck A, Moller S, Holst JJ. GLP-1-(936) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion. Am J Physiol (Endocrinol Metab) 2002;282:E873-9.
43. Vahl TP, Paty BW, Fuller BD, Prigeon RL, D'Alessio DA. Effects of GLP-1-(736) NH2, GLP-1-(7-37), and GLP-1-(936)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans. J Clin Endocrinol Metab 2003;88:1772-1779.
44. Meier JJ, Gethmann A, Nauck MA, Götze O, Schmitz F, Deacon CF, et al. The glucagon-like peptide-1 metabolite GLP-1-(936) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans. Am J Physiol (Endocrinol Metab) 2006;290:E 1118-1123.
45. Ørskov C, Wettergren A, Holst JJ. Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable. Diabetes 1993;42:658-661.
46. Meier JJ, Nauck MA, Kranz D, Holst JJ, Deacon CF, Gaeckler D, et al. Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes 2004;53:654-662.
47. Plamboeck A, Holst JJ, Carr RD, Deacon CF. Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. Diabetologia 2005;48:1882-1890.
48. Plamboeck A, Holst JJ, Carr RD, Deacon CF. Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both involved in regulating the metabolic stability of glucagon-like peptide-1 in vivo. Adv Exp Med Biol 2003;524:303-312.
49. Marguet D, Baggio L, Kobayashi T, Bernard AM, Pierres M, Nielsen PF, et al. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc Natl Acad Sci U S A 2000;97(12):6874-6879.
50. Yamada Y, Hayami T, Nakamura K, Kaisaki PJ, Someya Y, Wang CZ, et al. Human gastric inhibitory polypeptide receptor: cloning of the gene (GIPR) and cDNA. Genomics 1995;29:773-776.
51. Yamada Y, Seino Y. Physiology of GIP-a lesson from GIP receptor knockout mice. Horm Metab Res 2004;36:771-774.
52. Yamada Y, Miyawaki K, Tsukiyama K, Harada N, Yamada C, Seino Y. Pancreatic and extrapancreatic effects of gastric inhibitory polypeptide. Diabetes 2006;55(Suppl. 2):S86-91.
53. Miyawaki K, Yamada Y, Ban N, Ihara Y, Tsukiyama K, Zhou H, et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med 2002;8:738-742.
54. Thorens B. Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc Natl Acad Sci U S A 1992;89:8641-8645.
55. Thorens B, Porret A, Buhler L, Deng SP, Morel P, Widmann C. Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(939) an antagonist of the receptor. Diabetes 1993;42:1678-1682.
56. Wei Y, Mojsov S. Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett 1995;358:219-224.
57. Wei Y, Mojsov S. Distribution of GLP-1 and PACAP receptors in human tissues. Acta Physiol Scand 1996;157:355-357.
58. Drucker DJ, Philippe J, Mojsov S, Chick WL, Habener JF. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci U S A 1987;84:3434-3438.
59. Fehmann H-C, Habener JF. Insulinotropic hormone glucagon-like peptide-I (7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma β?TC-1 cells. Endocrinology 1992;130:159-166.
60. Brubaker PL, Drucker DJ. Minireview: Glucagonlike peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology 2004;145:2653-2659. Epub 2004 Mar 24.
61. Drucker DJ. The biology of incretin hormones. Cell Metabolism 2006;3:153-165.
62. Perfetti R, Zhou J, Doyle ME, Egan JM. Glucagonlike peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology 2000; 141:4600-4605.
63. Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem 2003;278:471-478.
64. Buteau J, El-Assaad W, Rhodes CJ, Rosenberg L, Joly E, Prentki M. Glucagon-like peptide-1 prevents beta cell glucolipotoxicity. Diabetologia 2004;47:806-815.
65. Farilla L, Bulotta A, Hirshberg B, Li Calzi S, Khoury N, Noushmehr H, et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 2003;144:5149-5158.
66. Miyawaki K, Yamada Y, Yano H, Niwa H, Ban N, Ihara Y, et al. Glucose intolerance caused by a defect in the entero-insular axis: A study in gastric inhibitory polypeptide receptor knockout mice. Proc Natl Acad Sci USA 1999;96:14843-14847.
67. Preitner F, Ibberson M, Franklin I, Binnert C, Pende M, Gjinovci A, et al. Gluco-incretins control insulin secretion at multiple levels as revealed in mice lacking GLP-1 and GIP receptors. J Clin Invest 2004;113:635-645.
68. Nauck MA, Heimesaat MM, Behle K, Holst JJ, Nauck MS, Ritzel R, et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 2002;87:1239-1246.
69. Ørskov C, Holst JJ, Nielsen OV. Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology 1988;123:2009-2013.
70. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 1993;38:665-673.
71. Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Ørskov C, Ritzel R, et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol (Endocrinol Metab) 1997;273: E 981-988.
72. Meier JJ, Kemmeries G, Holst JJ, Nauck MA. Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects. Diabetes 2005;54:2212-2218.
73. Little TJ, Pilichiewicz AN, Russo A, Phillips L, Jones KL, Nauck MA, et al. Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses. J Clin Endocrinol Metab 2006; 91: 1916-1923.
74. Flint A, Raben A, Astrup A, Holst JJ. Glucagonlike peptide-1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998;101:515-520.
75. Flint A, Raben A, Ersboll AK, Holst JJ, Astrup A. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int J Obes Relat Metab Disord 2001;25:781-792.
76. Gutzwiller JP, Drewe J, Göke B, Schmidt H, Rohrer B, Lareida J, et al. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol (Integr Regul Physiol) 1999;276:R 1541-1544.
77. Gutzwiller JP, Göke B, Drewe J, Hildebrand P, Ketterer S, Handschin D, et al. Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut 1999;44:81-86.
78. Verdich C, Flint A, Gutzwiller JP, Naslund E, Beglinger C, Hellstrom PM, et al. A meta-analysis of the effect of glucagon-like peptide-1 (736) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab 2001;86:4382-4389.
79. Burcelin R, Da Costa A, Drucker D, Thorens B. Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor. Diabetes 2001;50:1720-1728.
80. Wang Z, Wang RM, Owji AA, Smith DM, Ghatei MA, Bloom SR. Glucagon-like peptide-1 is a physiological incretin in rat. J Clin Invest 1995;95:417-421.
81. Kolligs F, Fehmann HC, Göke R, Göke B. Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide. Diabetes 1995;44:16-19.
82. Scrocchi LA, Brown TJ, MaClusky N, Brubaker PL, Auerbach AB, Joyner AL, et al. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med 1996;2:1254-1258.
83. Schirra J, Sturm K, Leicht P, Arnold R, Göke B, Katschinski M. Exendin (9-39) amide is an antagonist of glucagon-like peptide-1 (7-36) amide in humans. J Clin Invest 1998;101:1421-1430.
84. Schirra J, Nicolaus M, Roggel R, Katschinski M, Storr M, Woerle HJ, et al. Endogenous glucagonlike peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans. Gut 2006;55:243-251.
85. Edwards CMB, Todd JF, Mahmoudi M, Wang Z, Wang RM, Ghatei M.A, et al. GLP-1 has a physiological role in the control of postprandial glucose in man. Studies with the antagonist exendin 9-39. Diabetes 1999;48:86-93.
86. Nauck M, Stöckmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in Type 2 (noninsulin-dependent) diabetes. Diabetologia 1986;29:46-54.
87. Krarup T, Vilsbøll T, Madsbad S, Larsen S, Holst JJ, Højberg PV, et al. The incretin effect is preserved in glucose tolerant patients with chronic pancreatitis-but reduced in patients with chronic pancreatitis and secondary diabetes (abstract 0657). Diabetologia 2006;49(Suppl. 1):399.
88. Toft-Nielsen MB, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, Michelsen BK, et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001; 86: 3717-3723
89. Mitrakou A, Kelley D, Veneman T, Jenssen T, Pangburn T, Reilly J, et al. Contribution of abnormal muscle and liver glucose metabolism to postprandial hyperglycemia in NIDDM. Diabetes 1990;39:1381-1390.
90. Jones IR, Owens DR, Luzio S, Williams S, Hayes TM. The glucose dependent insulinotropic polypeptide response to oral glucose and mixed meals is increased in patients with type 2 (noninsulin-dependent) diabetes mellitus. Diabetologia 1989;32:668-677.
91. Creutzfeldt W, Ebert R, Nauck M, Stöckmann F. Disturbances of the entero-insular axis. Scand J Gastroenterol 1983;82(Suppl.):111-119.
92. Ding WG, Renström E, Rorsman P, Buschard K, Gromada J. Glucagon-like peptide I and glucosedependent insulinotropic polypeptide stimulate Ca2-induced secretion in rat alpha-cells by a protein kinase A-mediated mechanism. Diabetes 1997;46:792-800.
93. Jones IR, Owens DR, Moody AJ, Luzio SD, Morris T, Hayes TM. The effects of glucosedependent insulinotropic polypeptide infused at physiological concentrations in normal subjects and Type 2 (non-insulin-dependent) diabetic patients on glucose tolerance and B-cell secretion. Diabetologia 1987;30:707-712.
94. Nauck MA, Baller B, Meier JJ. Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes. Diabetes 2004; 53 (suppl. 3): S190-6.
95. Meier JJ, Nauck MA. Incretins and the development of type 2 diabetes. Curr Diab Rep 2006;6:194-201.
96. Kjems LL, Holst JJ, Vølund A, Madsbad S. The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 2003;52:380-386.
97. Meier JJ, Gallwitz B, Salmen S, Goetze O, Holst JJ, Schmidt WE, et al. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab 2003;88:2719-2725.
98. Nauck MA. Therapeutic potential of glucagon-like peptide 1 in type 2 diabetes. Diabetic Medicine 1996;13(Suppl.):S39-S43.
99. Amland PF, Jorde R, Aanderup S, Burhol PG, Giercksky K-E. Effects of intravenously infused porcine GIP on serum insulin, plasma C-peptide, and pancreatic polypeptide in non-insulin-dependent diabetes in the fasting state. Scand J Gastroenterol 1985;20:315-320.
100. Nauck MA, Schmidt WE, Ebert R, Striezel J, Cantor P, Hoffmann G, et al. Insulinotropic properties of synthetic gastric inhibitory peptide in man: interactions with glucose, phenylalanine, and cholezystokinin-8. J. Clin. Endocrinol. Metab. 1989;69:654-662.
101. Nauck MA, Homberger E, Siegel EG, Allen RC, Eaton RP, Ebert R, et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 1986;63:492-498.
102. Holst JJ, Gromada J, Nauck MA. The pathogenesis of NIDDM involves a defective expression of the GIP receptor. Diabetologia 1997;40:984-986.
103. Meier JJ, Nauck MA. Incretins and the development of type 2 diabetes. Curr Diab Rep 2006;6:194-201.
104. Vilsbøll T, Knop FK, Krarup T, Johansen A, Madsbad S, Larsen S, et al. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucosedependent insulinotropic polypeptide-regardless of etiology and phenotype. J Clin Endocrinol Metab. 2003;88:4897-4903.
105. Hinke SA, Lynn F, Ehses J, Pamir N, Manhart S, Kuhn-Wache K, et al. Glucose-dependent insulinotropic polypeptide (GIP): development of DP IV-resistant analogues with therapeutic potential. Adv Exp Med Biol 2003; 524: 293-301.
106. Gault VA, O'Harte FP, Harriott P, Mooney MH, Green BD, Flatt PR. Effects of the novel (Pro3) GIP antagonist and exendin (9-39) amide on GIP-and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin. Diabetologia 2003;46:222-230.
107. Irwin N, Gault VA, Green BD, Greer B, Harriott P, Bailey CJ, et al. Antidiabetic potential of two novel fatty acid derivatised, N-terminally modified analogues of glucose-dependent insulinotropic polypeptide (GIP): N-AcGIP(LysPAL16) and N-AcGIP(LysPAL37). Biol Chem 2005; 386: 679-687.
108. Pederson RA, Brown JC. Interaction of gastric inhibitory polypeptide, glucose, and arginine on insulin and glucagon secretion from the perfused rat pancreas. Endocrinol 1978;103:610-615.
109. Meier JJ, Gallwitz B, Siepmann N, Holst JJ, Deacon CF, Schmidt WE, et al. Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia. Diabetologia 2003;46:798-801.
110. Nauck MA, Kleine N, Ørskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993;36:741-744.
111. Toft-Nielsen MB, Madsbad S, Holst JJ. Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes. J Clin Endocrinol Metab 2001;86:3853-3860.
112. Nauck MA, Meier JJ. Glucagon-like peptide 1 (GLP-1) and its derivatives in the treatment of diabetes. Regul Pept 2005;128:135-148.
113. Willms B, Werner J, Holst JJ, Ørskov C, Creutzfeldt W, Nauck MA. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab 1996;81:327-332.
114. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002;359:824-830.
115. Meier JJ, Weyhe D, Michaely M, Senkal M, Zumtobel V, Nauck M.A, et al. Intravenous glucagon-like peptide 1 normalizes blood glucose after major surgery in patients with type 2 diabetes. Crit Care Med 2004;32:848-851.
116. Nauck MA, Walberg J, Vethacke A, El Ouaghlidi A, Senkal M, Holst JJ, et al. Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1. Regul Pept 2004;118:89-97.
117. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 1992;267:7402-7405.
118. Fehmann HC, Jiang J, Schweinfurth J, Wheeler MB, Boyd AE, 3rd, Goke B. Stable expression of the rat GLP-I receptor in CHO cells: activation and binding characteristics utilizing GLP-I(7-36)-amide, oxyntomodulin, exendin-4, and exendin(9-39). Peptides. 1994;15(3):453-456.
119. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092-1100.
120. Buse JB, Henry RR, Han J, Kim DD, Fineman M, Baron AD, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylureatreated patients with type 2 diabetes. Diabetes Care 2004;27:2628-2635.
121. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman M.S, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28: 1083-1091.
122. Zinman B, Hoogwerf B, Garcia SG, Milton D, Giaconia J, Kim D, et al. Safety and efficacy of exenatide in patients with type 2 diabetes mellitus using thiazolidindiones with or without metformin (abstract 117-OR). Diabetes 2006; 55(Suppl. 1):A 28.
123. Ratner RE, Stonehouse A, Gao H-Y, Poon T, Kim D. Exenatide maintains glycaemic control for 2 years in patients with type 2 diabetes: data from an ongoing, open-label study (abstract). Diabetologia 2005;48(Suppl. 1):A 288-289.
124. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005;143:559-569.
125. Nauck MA, Duran S, Kim D, Johns D, Northrup J, Festa A, et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 2006; 50: 259-267. Epub Dec. 8, 2006.
126. Knudsen LB, Nielsen PF, Huusfeldt PO, Johansen NL, Madsen K, Pedersen FZ, et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem 2000;43:1664-1669.
127. Agersø H, Jensen LB, Elbrond B, Rolan P, Zdravkovic M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 2002;45:195-202.
128. Elbrønd B, Jakobsen G, Larsen S, Agersø H, Jensen LB, Rolan P, et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care 2002;25:1398-1404.
129. Bjerre Knudsen L, Møller Knudsen S, Wilken M, Colding- Jørgensen M, Plum A, Agersø H, et al. Plasma protein binding of NN2211, a long-acting derivative of GLP-1, is important for its efficacy. Diabetes 2005;52(Suppl. 1):A 321-322.
130. Vilsbøll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, Courreges J, et al. Liraglutide significantly improves glycemic control, and lowers body weight without risk of either major or minor hypoglycemic episodes in subjects with type 2 diabetes (abstract 115-OR). Diabetes 2006;55(Suppl. 1):A 27-28.
131. Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): A 12-week, double-blind, randomized, controlled trial. Diabetes Care 2004;27:1335-1342.
132. Nauck MA, Hompesch M, Filipczak R, Le TD, Zdravkovic M, Gumprecht J. Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes. Exp Clin Endocrinol Diabetes. 2006;114:417-423.
133. Feinglos MN, Saad MF, Pi-Sunyer FX, An B, Santiago O. Effects of liraglutide (NN2211), a longacting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes. Diabetic Med 2005;22:1016-1023.
134. Gedulin BR, Smith P, Prickett KS, Tryon M, Barnhill S, Reynolds J, et al. Dose-response for glycaemic and metabolic changes 28 days after single injection of long-acting release exenatide in diabetic fatty Zucker rats. Diabetologia 2005;48:1380-1385.
135. Kim D, MacConnell L, Zhuang D, Scnabel C, Taylor K, Li W-I, et al. Safety and efficacy of a once-weekly, long-acting release formulation of exenatide over 15 weeks in patients with type 2 diabetes (abstract 487-P). Diabetes 2006;55(Suppl 1):A 116.
136. Kim JG, Baggio LL, Bridon DP, Castaigne JP, Robitaille MF, Jette L, et al. Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo. Diabetes 2003;52:751-759.
137. Baggio LL, Huang Q, Brown TJ, Drucker DJ. A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes 2004;53:2492-2500.
138. Kieffer TJ, McIntosh CH, Pederson RA. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 1995;136:3585-3596.
139. De Meester I, Durinx C, Bal G, Proost P, Struyf S, Goossens F, et al. Natural substrates of dipeptidyl peptidase IV. Adv Exp Med Biol 2000;477:67-87.
140. De Meester I, Lambeir AM, Proost P, Scharpe S. Dipeptidyl peptidase IV substrates. An update on in vitro peptide hydrolysis by human DPPIV. Adv Exp Med Biol 2003;524:3-17.
141. Deacon CF, Nauck MA, Meier J, Hücking K, Holst JJ. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab 2000;85:3575-3581.
142. Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 1995;80:952-957.
143. Ørskov C, Wettergren A, Holst JJ. Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day. Scand J Gastroenterol 1996;31:665-670.
144. Nauck MA, El-Ouaghlidi A, Gabrys B, Hücking K, Holst JJ, Deacon CF, et al. Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes. Regul Pept 2004;122:209-217.
145. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696-1705.
146. Åhren B, Simonsson E, Larsson H, Landin-Olsson M, Torgeirsson H, Jansson P-A et al. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 2002;25:869-875.
147. Herman GA, Stevens C, Van Dyck K, Bergman A, Yi B, De Smet M, et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther 2005;78:675-688.
148. Aschner P, Kipnes M, Lunceford J, Mickel C, Davies M, Williams-Herman D.
149. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care. 2006;29:2638-2643.
150. Åhren B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 2004;89:2078-2084.
151. Pratley RE, Jauffret-Kamel S, Galbreath E, Holmes D. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm Metab Res. 2006;38:423-428.
152. Åhren B, Pacini G, Foley JE, Schweizer A. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care 2005;28:1936-1940.
153. Åhren B, Gomis R, Standl E, Mills D, Schweizer A. Twelve-and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformintreated patients with type 2 diabetes. Diabetes Care 2004;27:2874-2880.
154. Matikainen N, Manttari S, Schweizer A, Ulvestad A, Mills D, Dunning BE, et al. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia. 2006;49:2049-2057. Epub 2006 Jul 1.
155. Dejager S, Lebeaut A, Couturier A, Schweizer A. Sustained reduction in HbA1c during one-year treatment with vildagliptin in patients with type 2 diabetes (T2DM) (abstract 120-OR). Diabetes 2006;55(Suppl. 1):A 29.
156. Rosenstock J, Baron MA, Schweizer A, Mills D, Dejager S. Vildagliptin is as effective as rosiglitazone in lowering HbA1c but without weight gain in drug-naive patients with type 2 diabetes (T2DM) (abstract 557-P). Diabetes 2006;55(Suppl. 1):A 133.
157. Hansen BC, Bjenning C, Bjerrre Knudsen L. Sustained appetite suppression and weight loss in obese rhesus monkeys treated with a long-acting GLP-1 derivative, NN2211 (abstract). Diabetologia 2001;44(Suppl. 1):A 196.
158. Nauck MA, Hompesch M, Filipicazak R, Le TDT, Nielsen LL, Zdravkovic M, et al. Liraglutide significantly improves glycemic control and reduces body weight compared with glimepiride as add-on to metformin in type 2 diabetes (abstract). Diabetes 2004;53(Suppl. 2):A 83.
159. Scott R, Herman G, Zhao P, Chen X, Wu M, Stein P. Twelve-week efficacy and tolerability of MK-0431, a dipeptidyl peptidase IV (DPP-IV) inhibitor, in the treatment of type 2 diabetes (T2D) (abstract 41-OR). Diabetes 2005;54(Suppl. 1):A 10-11.
160. Hanefeld M, Herman G, Mickel C, McGowan A, Wu M, Zhao P, et al. Effect of MK-0431, a dipeptidyl peptidase IV (DPP-IV) inhibitor, on glycemic control after 12 weeks in patients with type 2 diabetes (abstract 791). Diabetologia 2005;48(Suppl. 1):A 287-288.
161. Brazg R, Thomas K, Zhao P, Xu L, Chen X, Stein P. Effect of adding MK-0431 to ongoing metformin therapy in type 2 diabetic patients who have inadequate glycemic control on metformin (abstract). Diabetes 2005;54(Suppl. 1):A 3.
162. Demuth HU, McIntosh CH, Pederson RA. Type 2 diabetes-therapy with dipeptidyl peptidase IV inhibitors. Biochim Biophys Acta 2005;1751:33-44.
163. Blonde L, Klein EJ, Han J, Zhang B, Mac SM, Poon TH, et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006;8:436-447.
164. Kolterman O, Gottlieb A, Prickett K, Gaines E, Young A. Dose-response for inhibition of glucagon secretion and gastric emptying by synthetic exendin-4 (AC2993) in subjects with Type 2 diabetes (abstract). Diabetes 2000;49 (Suppl. 1):A 114.
165. Dardik B, Valentin M, Schwartzkopf C, Gutierrez C, Stevens D, Russell ME, et al. NVP-LAF237, a dipeptidyl peptidase IV inhibitor, improves glucose tolerance and delays gastric emptying in obese insulin resistant Cynomolgus monkeys (abstract 1292-P). Diabetes 2003;52(Suppl. 1):A 322.
166. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006;29:1963-1972.
167. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2006;49:1711-1721.
168. Yki-Järvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care 2001; 24:: 758-767.
169. Yki-Järvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care 2001;24:758-767.
170. UK prospective diabetes study (UKPDS) group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) Lancet 1998;352:854-865.
171. Williams-Herman D, Goldstein BJ, Feinglos MN, Lunceford J, Johnson J. Initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin provides substantial glycemic improvement and HBA1c goal attainment in patients with type 2 diabetes mellitus (T2DM) (abstract P880). Diabetic Med 2006;23(Suppl. 4):319.
172. Yki-Järvinen H. Thiazolidinediones. N Engl J Med 2004;351:1106-1118.
173. Yki-Järvinen H. The PROactive study: some answers, many questions. Lancet 2005;366:1241-1242.
174. Fineman MS, Shen LZ, Taylor K, Kim DD, Baron AD. Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes. Diabetes Metab Res Rev 2004;20:411-417.
175. Nauck MA, Hompesch M, Filipczak R, Le TD, Zdravkovic M, Gumprecht J. Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with Type 2 diabetes. Exp Clin Endocrinol Diabetes 2006;114:417-423.
176. Kolterman OG, Kim DD, Shen L, Ruggles JA, Nielsen LL, Fineman M.S, et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am Health Syst Pharm 2005;62:173-181.
177. Linnebjerg H, Kothare PA, Skrivanek Z, de la Pena A, Atkins M, Ernest CS, et al. Exenatide: effect of injection time on postprandial glucose in patients with Type 2 diabetes. Diabet Med 2006;23:240-245.
178. Linnebjerg H, Park S, Kothare P, Trautmann M, Mace K, Fineman M, et al. Effects of exenatide on gastric emptying and postprandial glucose in type 2 diabetes (abstract 116-OR). Diabetes 2006;55 (Suppl. 1):A 28.
179. Fineman MS, Bicsak TA, Shen LZ, Taylor K, Gaines E, Varns A, et al. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 2003;26:2370-2377.
180. Herman GA, Bergman A, Stevens C, Kotey P, Yi B, Zhao P, et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 2006; 91: 4612-4619.
181. Riddle MC, Rosenstock J, Gerich J. The treat-totarget trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080-3086.
182. Yki-Järvinen H, Kauppinen-Makelin R, Tiikkainen M, Vahatalo M, Virtamo H, Nikkila K, et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 2006;49:442-451.
183. El-Ouaghlidi A, Rehring E, Schweizer A, Holmes D, Nauck MA. The dipeptidyl peptidase IV inhibitor LAF237 does not accentuate reactive hypoglycaemia caused by the sulfonylurea glibenclamide administered before an oral glucose load in healthy subjects (abstract 507-P). Diabetes 2003;52(Suppl. 1):A 118.
184. Henry RR, Ratner RE, Stonehouse AH, Guan X, Poon T, Malone JK, et al. Exenatide maintained glycemic control with associated weight reduction over 2 years in patients with type 2 diabetes (abstract 485-P). Diabetes 2006;55(Suppl. 1):A 116.
185. Ritzel R, Ørskov C, Holst JJ, Nauck MA. Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-responserelationships. Diabetologia 1995;38:720-725.
186. Buse JB, Henry R, Han J, Kim DD, Fineman MS, Baron AD. Effect of exenatide (exendin-4) on glycemic control and safety over 30 weeks in sulfonylurea-treated patients with type 2 diabetes (abstract 352-OR). Diabetes 2004;53(Suppl. 2):A 82.
187. Dang NH, Morimoto C. CD26: an expanding role in immune regulation and cancer. Histol. Histopathol. 2002;17(4):1213-1226.
188. Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006;49:2564-2571. [Epub 2006 Sep 26.]
189. Haffner SM, Lehto S, Ronnemaa T, Pyorälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-234.
190. U.K. prospective diabetes study group. U.K. prospective diabetes study 16: Overview of 6 years therapy of type II diabetes: A progressive disease (Perspectives in diabetes). Diabetes 1995;44:1249-1258.
191. Levy J, Atkinson AB, Bell PM, McCance DR, Hadden DR. Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study. Diabet Med 1998;15:290-296.
192. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. J Am Med Ass 1999;281:2005-2012.
193. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-2443.
194. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003;52:102-110.
195. Gepts W. Pathologic anatomy of the pancreas in juvenile diabetes mellitus. Diabetes. 1965;14(10):619-633.
196. Meier JJ, Bhushan A, Butler AE, Rizza RA, Butler PC. Sustained beta cell apoptosis in patients with longstanding type 1 diabetes: indirect evidence for islet regeneration? Diabetologia. 2005;48:2221-2228. [Epub 2005 Oct 5.]
197. Meier JJ, Bhushan A, Butler PC. The potential for stem cell therapy in diabetes. Pediatr Res. 2006;59:65R-73R.
198. Buteau J, Roduit R, Susini S, Prentki M. Glucagonlike peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells. Diabetologia 1999;42:856-864.
199. Buteau J, Foisy S, Joly E, Prentki M. Glucagon-like peptide 1 induces pancreatic beta-cell proliferation via transactivation of the epidermal growth factor receptor. Diabetes 2003;52:124-132.
200. Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999;48:2270-2276.
201. Tourrel C, Bailbe D, Meile MJ, Kergoat M, Portha B. Glucagon-like peptide-1 and exendin-4 stimulate betacell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes 2001;50: 1562-1570.
202. Tourrel C, Bailbe D, Lacorne M, Meile MJ, Kergoat M, Portha B. Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4. Diabetes 2002;51:1443-1452.
203. Stoffers DA, Desai BM, DeLeon DD, Simmons RA. Neonatal exendin-4 prevents the development of diabetes in the intrauterine growth retarded rat. Diabetes 2003;52:734-740.
204. Farilla L, Hui H, Bertolotto C, Kang E, Bulotta A, Di Mario U, et al. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats Endocrinology. 2002; 143: 4397-4408.
205. De Leon DD, Deng S, Madani R, Ahima RS, Drucker DJ, Stoffers DA. Role of endogenous glucagon-like peptide-1 in islet regeneration after partial pancreatectomy. Diabetes 2003;52:365-371.
206. Farilla L, Hui H, Bertolotto C, Kang E, Bulotta A, Di Mario U, et al. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 2002;143:4397-4408.
207. De Leon DD, Deng S, Madani R, Ahima RS, Drucker DJ, Stoffers DA. Role of endogenous glucagon-like peptide-1 in islet regeneration after partial pancreatectomy. Diabetes 2003;52:365-371.
208. Rolin B, Larsen MO, Gotfredsen CF, Deacon CF, Carr RD, Wilken M, et al. The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. Am J Physiol (Endocrinol Metab) 2002;283:E 745-752.
209. Bregenholt S, Moldrup A, Blume N, Karlsen AE, Nissen Friedrichsen B, Tornhave D, et al. The longacting glucagon-like peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro. Biochem Biophys Res Commun. 2005;330:577-584.
210. Pospisilik JA, Martin J, Doty T, Ehses JA, Pamir N, Lynn FC, et al. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes 2003;52:741-750.
211. Mu J, Woods J, Zhou YP, Roy RS, Li Z, Zycband E, et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic β-cell mass and function in a rodent model of type 2 diabetes. Diabetes 2006;55:1695-1704.
212. Butler AE, Janson J, Soeller WC, Butler PC. Increased beta-cell apoptosis prevents adaptive increase in beta-cell mass in mouse model of type 2 diabetes: evidence for role of islet amyloid formation rather than direct action of amyloid. Diabetes. 2003;52(9):2304-2314.
213. Larsen MO, Rolin B, Sturis J, Wilken M, Carr RD, Porksen N, et al. Measurements of insulin responses as predictive markers of pancreatic beta-cell mass in normal and beta-cell-reduced lean and obese Gottingen minipigs in vivo. Am J Physiol Endocrinol Metab. 2006;290:E670-7. [Epub 2005 Nov 8.]
214. Stoffers DA, Kieffer TJ, Hussain MA, Drucker DJ, Bonner-Weir S, Habener JF, et al. Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes 2000;49:741-748.
215. Hui H, Wright C, Perfetti R. Glucagon-like peptide 1 induces differentiation of islet duodenal homeobox-1-positive pancreatic ductal cells into insulin-secreting cells. Diabetes 2001; 50: 785-796.
216. Hui H, Nourparvar A, Zhao X, Perfetti R. Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5'-adenosine monophosphate-dependent protein kinase A-and a phosphatidylinositol 3-kinase-dependent pathway. Endocrinology 2003; 144: 1444-1455.
217. Abraham EJ, Leech CA, Lin JC, Zulewski H, Habener JF. Insulinotropic hormone glucagonlike peptide-1 differentiation of human pancreatic islet-derived progenitor cells into insulin-producing cells. Endocrinology 2002;143:3152-3161.
218. Ritzel RA, Butler AE, Rizza RA, Veldhuis JD, Butler PC. Relationship between beta-cell mass and fasting blood glucose concentration in humans. Diabetes Care 2006;29:717-718.
219. Duttaroy A, Voelker F, Zhang X, Ren X, Merriam K, Qiu L, et al. The DPP-4 inhibitor vildagliptin increases pancreatic beta cell mass in rodents (abstract 481). Diabetologia 2005;48(Suppl. 1):A 178.
220. Gros R, You X, Baggio LL, Kabir MG, Sadi AM, Mungrue IN, et al. Cardiac function in mice lacking the glucagon-like peptide-1 receptor. Endocrinology 2003;144:2242-2252.
221. Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 2005;54:146-151.
222. Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, Elahi D, et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004; 109: 962-965. [Epub 2004 Feb .23.]
223. Nikolaidis LA, Elahi D, Hentosz T, Doverspike A, Huerbin R, Zourelias L, et al. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 2004;110:955-961.
224. Kolterman OG, Buse JB, Fineman MS, Gaines E, Heintz S, Bicsak TA, et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003;88:3082-3089.
225. Juhl CB, Hollingdal M, Sturis J, Jakobsen G, Agerso H, Veldhuis J, et al. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes 2002; 51: 424-429.
226. Quddusi S, Vahl TP, Hanson K, Prigeon RL, D'Alessio DA. Differential effects of acute and extended infusions of glucagon-like peptide-1 on firstand second-phase insulin secretion in diabetic and nondiabetic humans. Diabetes Care 2003;26:791-798.
227. Fehse FC, Trautmann M, Holst JJ, Halseth AE, Fineman MS, Kim D, et al. Effects of exenatide on first and second phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes (Abstract). Diabetes 2004;53(Suppl. 2):A 83.
228. Polonsky KS, Given BD, Hirsch LJ, Tillil H, Shapiro ET, Frank BH, et al. Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N Engl J Med 1988;318:1231-1239.
229. Rachman J, Gribble FM, Levy JC, Turner RC. Near-normalization of diurnal glucose concentrations by continuous administration of glucagon-like peptide 1 (GLP-1) in subjects with NIDDM. Diabetologia 1997;40:205-211.
230. Gerich JE. Abnormal glucagon secretion in type 2 (noninsulin-dependent) diabetes mellitus: Causes and consequences. In: Creutzfeldt W, Lefèbvre P, editors. Diabetes mellitus: Pathophysiology and therapy. Berlin, Heidelberg: Springer Verlag; 1989, 127-133.
231. Degn KB, Brock B, Juhl CB, Djurhuus CB, Grubert J, Kim D, et al. Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. Diabetes 2004;53:2397-2403.
232. Nauck M, El-Ouaghlidi A, Hompesch M, Jacobsen J, Elbrønd B. No impairment of hypoglycemia counterregulation via glucagon with NN2211, a GLP-1 derivative, in subjects with type 2 diabetes (abstract 550-P). Diabetes 2003;52(Suppl. 1)(A 128).
233. Fehmann HC, Göke R, Göke B. Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide. Endocr Rev 1995;16:390-410.
234. Rahier J, Goebbels RM, Henquin JC. Cellular composition of the human diabetic pancreas. Diabetologia 1983;24:366-371.
235. Buteau J, Foisy S, Rhodes CJ, Carpenter L, Biden TJ, Prentki M. Protein kinase Czeta activation mediates glucagon-like peptide-1-induced pancreatic beta-cell proliferation. Diabetes 2001;50:2237-2243.
236. Li Y, Cao X, Li LX, Brubaker PL, Edlund H, Drucker DJ. β-cell PDX1 expression is essential for the glucoregulatory, proliferative, and cytoprotective actions of glucagon-like peptide-1. Diabetes 2005;54:482-491.
237. Bregenholdt S, Moldrup A, B. Knudsen L, Petersen JS. The GLP-1 derivative NN2211 inhibits cytokine-induced apoptosis in primary rat β-cells (abstracts). Diabetes 2001;50(Suppl. 1):A 31.
238. Phillips WT, Salman UA, McMahan CA, Schwartz JG. Accelerated gastric emptying in hypertensive subjects. J Nucl Med 1997;38:207-211.
239. Colditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 1995;122:481-486.
240. Poon T, Nelson P, Shen L, Mihm M, Taylor K, Fineman M, et al. Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study. Diabetes Technol Ther 2005;7:467-477.
241. Harder H, Nielsen L, Tu DT, Astrup A. The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes. Diabetes Care 2004;27:1915-1921.
242. Raz I, Hanefeld M, Xu L, Caria C, Davies M, Williams-Herman D, et al. Sitagliptin monotherapy improved glycemic control and beta-cell function after 18 weeks in patients with type 2 diabetes (T2DM) (abstract 1996-PO). Diabetes 2006;55(Suppl. 1):A 462.
243. Nonoka K, Kakikawa T, Sato A, Okuyama K, Fujimoto G, Hayashi N, et al. Twelve-week efficacy and tolerability of sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, in Japanese patients with type 2 diabetes (Abstract 0038). Diabetologia 2006;49(Suppl. 1):25.
244. Karasik A, Charbonnell B, Liu J, Wu M, Meehan A, Meininger G. Sitagliptin added to ongoing metformin therapy enhanced glycemic control and beta-cell function in patients with type 2 diabetes (abstract 501-P). Diabetes 2006;55(Suppl. 1):A 119-120.
245. Nauck MA, Meininger G, Sheng D, Terranella L, Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared to the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: A randomized double-blind, non-inferiority trial. Diabetes Obesity Metab 2007;9:194-205.
246. Rosenstock J, Brazg R, Andryuk PJ, McCrary Sisk C, Lu K, Stein P. Addition of sitagliptin to pioglitazone improved glycemic control with neutral weight effect over 24 weeks in inadequately controlled type 2 diabetes (T2DM) (abstract 556-P). Diabetes 2006;55(Suppl. 1):A 132-133.
247. Pratley R, Galbreath E. Twelve-week monotherapy with the DPP-4 inhibitor, LAF 237 improves glycemic control in patients with type 2 diabetes (T2DM) (abstract 355-OR). Diabetes 2004;53(Suppl. 2):A 83.
248. Kikuchi M, Abe N, Kato M, Terao S, Holmes D, Mimori N. Vildagliptin decreases HbA1c after 12 weeks treatment in Japanese patients with type 2 diabetes (abstract 0789). Diabetologia 2006; 49(suppl. 1): 478.
249. Dejager S, Baron MA, Razac S, Foley JE, Dickinson S, Schweizer A. Efficacy of vildagliptin in drug-naïve patients with type 2 diabetes (abstract 0791). Diabetologia 2006;49(Suppl. 1):479.
250. Garber A, Camisasca RP, Ehrsam E, Collober-Maugeais C, Rochotte E, Lebeaut A. Vildagliptin added to metformin improves glycemic control and may mitigate metformin-induced GI side effects in patients with type 2 diabetes (T2DM) (abstract 121-OR). Diabetes 2006;55(Suppl. 1):A 29.